U.S. markets open in 1 hour 55 minutes
  • S&P Futures

    4,541.75
    +5.25 (+0.12%)
     
  • Dow Futures

    35,568.00
    +11.00 (+0.03%)
     
  • Nasdaq Futures

    15,376.25
    +35.25 (+0.23%)
     
  • Russell 2000 Futures

    2,288.40
    -0.40 (-0.02%)
     
  • Crude Oil

    84.66
    +0.90 (+1.07%)
     
  • Gold

    1,802.00
    +5.70 (+0.32%)
     
  • Silver

    24.50
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1623
    -0.0023 (-0.20%)
     
  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     
  • Vix

    15.88
    +0.87 (+5.80%)
     
  • GBP/USD

    1.3767
    +0.0008 (+0.06%)
     
  • USD/JPY

    113.6580
    +0.1980 (+0.17%)
     
  • BTC-USD

    63,029.55
    +2,190.05 (+3.60%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,235.50
    +30.95 (+0.43%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FREEHOLD, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that it will be presenting at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 – 30, 2021.

David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare will present on Thursday, September 30th at 10:50 AM Eastern Time. Management will also participate in one-on-one meetings with investors throughout the conference.

Investors can register for the conference here: https://www.benzinga.com/events/small-cap/healthcare/.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com